Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

The diagnostic accuracy of 68 Ga-PSMA-PET/CT in primary staging of patients with high-risk nonmetastatic prostate cancer treated with radical prostatectomy: A single-center cohort analysis

P. Rajwa, J. Heidenreich, A. Drzezga, M. Schmidt, SF. Shariat, A. Heidenreich

. 2024 ; 84 (1) : 74-78. [pub] 20230926

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24000147

BACKGROUND: 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) is a recommended imaging modality for patients with recurrent prostate cancer (PCa). Its routine implementation before radical prostatectomy (RP) may allow avoiding undertreatment. We aimed to analyze the diagnostic accuracy of 68 Ga-PSMA-PET/CT for pelvic lymph node metastases in a large cohort of patients treated with RP and extended pelvic lymph node dissection (ePLND) for high-risk PCa. METHODS: This is a retrospective analysis of an institutional database of patients who underwent 68 Ga-PSMA-PET/CT before RP and ePLND for high-risk PCa. The diagnostic estimates of 68 Ga-PSMA-PET/CT with 95% confidence intervals (CIs) for lymph node involvement were calculated. RESULTS: We included 165 high-risk PCa patients. The median PSA value was 24.5 ng/mL (range: 6.7-185) and all the patients had biopsy Grade Group 4-5. In total, 46 (28%) of patients had clinical lymph node involvement at 68 Ga-PSMA-PET/CT. A mean number of resected lymph nodes per patient was 22 (range: 15-45) and 149 (4.2%) of all resected nodes were positive for lymph node metastasis at final pathology. The diagnostic estimates for the detection of pN+ disease at RP were as follows: sensitivity 63% (95% CI: 51-75), specificity 97% (95% CI: 91-99), positive predictive value 94% (95% CI: 82-99), and negative predictive value 79% (95% CI: 70-86). The total accuracy of PSMA-PET was 83% (95% CI: 76-88). CONCLUSION: Our analyses support high specificity and positive predictive value of pretreatment 68 Ga-PSMA PET/CT for the detection of pelvic lymph node metastasis in patients treated with RP for high-risk PCa. While a positive finding should be considered as robust indicator for clinical decision-making, a negative result cannot reliably rule out the presence of lymph node involvement in high-risk PCa; there is a need for advanced risk stratification in those patients.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000147
003      
CZ-PrNML
005      
20240213093002.0
007      
ta
008      
240109s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/pros.24627 $2 doi
035    __
$a (PubMed)37750292
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Rajwa, Pawel $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, Medical University of Silesia, Zabrze, Poland $1 https://orcid.org/0000000340736584
245    14
$a The diagnostic accuracy of 68 Ga-PSMA-PET/CT in primary staging of patients with high-risk nonmetastatic prostate cancer treated with radical prostatectomy: A single-center cohort analysis / $c P. Rajwa, J. Heidenreich, A. Drzezga, M. Schmidt, SF. Shariat, A. Heidenreich
520    9_
$a BACKGROUND: 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) is a recommended imaging modality for patients with recurrent prostate cancer (PCa). Its routine implementation before radical prostatectomy (RP) may allow avoiding undertreatment. We aimed to analyze the diagnostic accuracy of 68 Ga-PSMA-PET/CT for pelvic lymph node metastases in a large cohort of patients treated with RP and extended pelvic lymph node dissection (ePLND) for high-risk PCa. METHODS: This is a retrospective analysis of an institutional database of patients who underwent 68 Ga-PSMA-PET/CT before RP and ePLND for high-risk PCa. The diagnostic estimates of 68 Ga-PSMA-PET/CT with 95% confidence intervals (CIs) for lymph node involvement were calculated. RESULTS: We included 165 high-risk PCa patients. The median PSA value was 24.5 ng/mL (range: 6.7-185) and all the patients had biopsy Grade Group 4-5. In total, 46 (28%) of patients had clinical lymph node involvement at 68 Ga-PSMA-PET/CT. A mean number of resected lymph nodes per patient was 22 (range: 15-45) and 149 (4.2%) of all resected nodes were positive for lymph node metastasis at final pathology. The diagnostic estimates for the detection of pN+ disease at RP were as follows: sensitivity 63% (95% CI: 51-75), specificity 97% (95% CI: 91-99), positive predictive value 94% (95% CI: 82-99), and negative predictive value 79% (95% CI: 70-86). The total accuracy of PSMA-PET was 83% (95% CI: 76-88). CONCLUSION: Our analyses support high specificity and positive predictive value of pretreatment 68 Ga-PSMA PET/CT for the detection of pelvic lymph node metastasis in patients treated with RP for high-risk PCa. While a positive finding should be considered as robust indicator for clinical decision-making, a negative result cannot reliably rule out the presence of lymph node involvement in high-risk PCa; there is a need for advanced risk stratification in those patients.
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    12
$a PET/CT $x metody $7 D000072078
650    _2
$a prostata $x diagnostické zobrazování $x chirurgie $x patologie $7 D011467
650    _2
$a lymfatické metastázy $x diagnostické zobrazování $x patologie $7 D008207
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a lokální recidiva nádoru $x patologie $7 D009364
650    _2
$a prostatektomie $7 D011468
650    12
$a nádory prostaty $x diagnostické zobrazování $x chirurgie $x patologie $7 D011471
650    _2
$a radioizotopy galia $7 D005710
650    _2
$a staging nádorů $7 D009367
655    _2
$a časopisecké články $7 D016428
700    1_
$a Heidenreich, Julian $u Department of Urology, Uro-Oncology, Robot-Assisted and Specialized Urologic Surgery, University Hospital Cologne, Cologne, Germany
700    1_
$a Drzezga, Alexander $u Department of Nuclear Medicine, Faculty of Medicine, University Hospital Cologne, Cologne, Germany
700    1_
$a Schmidt, Matthias $u Department of Nuclear Medicine, Faculty of Medicine, University Hospital Cologne, Cologne, Germany
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia $u Department of Urology, Weill Cornell Medical College, New York, New York, USA $u Department of Urology, University of Texas Southwestern, Dallas, Texas, USA
700    1_
$a Heidenreich, Axel $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, Uro-Oncology, Robot-Assisted and Specialized Urologic Surgery, University Hospital Cologne, Cologne, Germany
773    0_
$w MED00010484 $t The Prostate $x 1097-0045 $g Roč. 84, č. 1 (2024), s. 74-78
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37750292 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213092959 $b ABA008
999    __
$a ok $b bmc $g 2049060 $s 1209841
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 84 $c 1 $d 74-78 $e 20230926 $i 1097-0045 $m The Prostate $n Prostate $x MED00010484
LZP    __
$a Pubmed-20240109

Find record

Citation metrics

Archiving options